Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury
Andrew Gibson, Sean Hammond, Kanoot Jaruthamsophon, Sharin E. Roth, Merrie Mosedale, Dean J. Naisbitt
Abstract
Tolvaptan is an effective drug for the treatment of autosomal dominant polycystic kidney disease, but its use is associated with a significant risk of liver injury in a small number of patients. Herein we describe the presence of tolvaptan- and tolvaptan-metabolite-responsive T cell clones within the peripheral circulation of patients with liver injury. Drug treatment of the clones resulted in a proliferative response and secretion of IFN-γ, IL-13, and the cytolytic molecule granzyme B. Future work should explore pathways of tolvaptan driven T cell activation and the role of T cells in the disease pathogenesis.
Topics & Concepts
TolvaptanLiver injuryMedicineMetaboliteDrugPharmacologyGranzymePathogenesisGranzyme BAcute kidney injuryInternal medicineImmunologyT cellCD8PerforinHyponatremiaImmune systemGenetic and Kidney Cyst DiseasesBiomedical Research and PathophysiologyRenal Diseases and Glomerulopathies